Background: Previous studies of the gemcitabine-pemetrexed combination in patients with late-stage non-smallcell lung cancer (NSCLC) utilized a 90-min delay between gemcitabine and pemetrexed administration. This phase II study evaluated activity when these agents were administered in rapid succession. Results: Fifty-four enrolled patients (53 treated) completed a median of four cycles. Median dose intensity was 84%
introduction
Lung cancer remains the leading cause of cancer deaths worldwide, responsible for 1.2 million deaths annually [1] . Non-small-cell lung cancer (NSCLC) comprises 75%-80% of all lung cancer diagnoses, and the majority of these patients present with locally advanced or metastatic disease, ineligible for curative therapy [2] . For patients with advanced-stage disease, treatment is aimed at palliation with quality-of-life preservation.
Platinum-based chemotherapy is preferred for patients with good performance status (PS); however, no specific regimen has shown superiority in prolonging overall survival (OS) [3, 4] . Non-platinum combinations have also been explored to find a regimen with optimal antitumor activity without the toxic effects associated with cisplatin-or carboplatin-based regimens. Several randomized phase III trials have suggested that non-platinum-containing doublets maybe as efficacious as platinum doublets, with comparable or reduced toxicity [5] [6] [7] . Current American Society of Clinical Oncology guidelines recommend either a platinum-or non-platinum-based doublet as first-line therapy in this setting [8] .
Gemcitabine (GemzarÒ, Eli Lilly and Company, Indianapolis, IN) is a pyrimidine antimetabolite [9] that has demonstrated independent antitumor activity in diverse tumor types. Pemetrexed (AlimtaÒ, Eli Lilly and Company) is a multitargeted antifolate that inhibits thymidylate synthase, dihydroflate reductase, and glycinamide ribonucleotide formyltransferase [10, 11] . It is approved as a single agent for second-line treatment of locally advanced or metastatic NSCLC. Preclinical studies of gemcitabine and pemetrexed suggest that these agents may have synergistic cytotoxic activity when combined [12, 13] . A phase I trial by Adjei et al. [14] established the preferred sequence as 21-day cycles of gemcitabine 1250 mg/m 2 on days 1 and 8, and pemetrexed 500 mg/m 2 given 90 min after day 8 gemcitabine.
original article Subsequent phase II studies in advanced NSCLC employed a 90-min delay between gemcitabine and pemetrexed administration and demonstrated efficacy worthy of further study [15, 16] . Recently, a pharmacokinetic study conducted by Dy et al. [17] found that the delay between gemcitabine and pemetrexed administration maybe unnecessary. In that trial, 14 patients received pemetrexed immediately following day 8 gemcitabine. One patient experienced a partial response (PR) (greater than or equal to a 30% decrease from baseline in the sum of the longest diameters of the target lesions and either incomplete response, stable disease or lack of disease progression of the nontarget lesions), eight patients had stable disease (SD) (target lesions not qualifying for CR, PR or progression, and no progression of nontarget lesions, and no new lesions) for five or more cycles, and toxic effects were mild to moderate in severity [17] .
The demonstrated efficacy and modest toxicity profile of the gemcitabine-pemetrexed combination make it attractive for further study, and eliminating the 90-min dosing delay could improve the regimen's convenience.
materials and methods

eligibility criteria
Eligible patients had a histologic or cytologic diagnosis of locally advanced or metastatic NSCLC [18] not amenable to curative surgery. All patients were ‡18 years of age with measurable disease, an Eastern Cooperative Oncology Group PS of zero or one, and estimated life expectancy ‡12 weeks. Adequate bone marrow reserve and organ function were required, defined as an absolute neutrophil count (ANC) ‡2.0 · 10 9 /l; hemoglobin ‡9 g/dl; platelets ‡100 · 10 9 /l; bilirubin £1.5 · institutional upper limit of normal (ULN); alkaline phosphatase, aspartate transaminase, and alanine transaminase £3.0 · institutional ULN; and calculated creatinine clearance ‡45 ml/min as per Cockcroft and Gault [19] . Patients with treated, stable brain metastases were eligible. Whole pelvic radiation was not permitted, but prior radiation to <25% of the bone marrow was, provided radiotherapy was completed ‡4 weeks before study enrollment. Patients were required to use appropriate contraceptive methods, to comply with vitamin supplementation, and to be able to interrupt aspirin or nonsteroidal anti-inflammatory therapy before pemetrexed treatment. Patients with prior systemic chemotherapy, chemotherapy for pleurodesis, biological therapy, or immunotherapy were excluded, as were those with second primary malignancies, active infection, recent significant weight loss, symptomatic brain metastases, or other serious systemic disorders. Management of clinically significant third-space fluid collections was required before entry. The trial was conducted at eight centers in the United States. Prior to study initiation, each center's institutional review board approved the protocol. The trial was conducted in compliance with good clinical practice guidelines, federal and institutional guidelines, and the Declaration of Helsinki. Patients provided written informed consent before undergoing any study procedure or receiving any study therapy.
study design and sample size
This open-label phase II trial was designed to enroll up to 48 qualified patients in a two-stage, sequential manner. Three responses in the first 18 patients were required to continue to full accrual; the regimen would be considered worthy of further investigation if responses were seen in ‡13 of 48 total patients (27%). The probability of stopping early after 18 patients was at least 48% if the true response rate (RR) was £15% (H 0 ) and £2.4% if the true RR was as high as 35% (H a To minimize pemetrexed-associated toxic effects, patients received folic acid (350-600 lg/day orally) and vitamin B 12 (1000 lg by i.m. injection approximately every 9 weeks) beginning 1-2 weeks before the first pemetrexed dose and continuing until 3 weeks after the last pemetrexed dose. Patients also received dexamethasone (4 mg or equivalent orally twice daily on the day before, day of, and day after pemetrexed administration) for rash prophylaxis.
Patients received full supportive care while on study: recommended prophylactic antiemetic regimen including a 5-HT3 antagonist, granulocyte colony-stimulating factor support (for patients with ANC <0.5 · 10 9 /l, fever, or documented infection while neutropenic), and leucovorin (for grade 4 leukopenia, grade 4 neutropenia >3 days, grade 4 thrombocytopenia, bleeding associated with grade 3 thrombocytopenia, or grade 3 or 4 mucositis).
baseline and treatment assessments
At baseline and before day 1 of each cycle, patients underwent physical examination and PS assessment, tumor measurement, and toxicity grading using National Cancer Institute Common Toxicity Criteria version 2.0 (CTC v2.0) [20] . Chemistries were obtained on days 1 and 8, and hematologic assessments were carried out on days 1, 8, and 15.
ANC, platelets, and nonhematologic toxic effects were clinically evaluated on day 8. ANC 500-1000 · 10 9 cells/l or platelets 50 000-75 000 · 10 9 cells/l required a 25% dose reduction for both gemcitabine and pemetrexed. Both drugs were withheld for ANC <500 · 10 9 cells/l or platelets <50 000 · 10 9 cells/l. Grade 3 nonhematologic toxic effects (except nausea, vomiting, and alopecia) required a 25% dose reduction for both drugs on day 8. Treatment was withheld for grade 4 nonhematologic toxic effects. Patients whose treatment was withheld on day 8 maintained the cycle schedule and subsequent cycles were to be given on time provided toxic effects had resolved to grade £2. Day 1 treatment was given only if ANC ‡1.5 · 10 9 cells/l and platelets ‡100 · 10 9 cells/l.
Subsequent to cycle 1, equal dose reductions to both drugs were based on nadir neutrophil and platelet counts. Patients requiring day 1 dose reductions continued to receive reduced doses for the remainder of the study. Patients were discontinued from the study for more than two day 1 dose reductions, >42 days to recover from toxic effects, or toxic effects deemed unacceptable by patient or physician.
study end points
The trial's primary end point was tumor RR, defined as investigatorreported best response throughout therapy and follow-up using Response Evaluation Criteria in Solid Tumors [21] . Time-to-event variables (defined as follows) and safety were secondary objectives. Time-to-objective tumor response was the time from enrollment to the first observation of an objective response. Duration of response was the time from first objective assessment of a complete response (CR) (disappearance of all target and nontarget lesions and normalization of tumour marker levels, with no new lesions or disease-related symptoms) or PR to the first observation of PD or death from any cause. Time-to-treatment failure (TTF) was the time from enrollment to the first observation of PD, death from any cause, or early Annals of Oncology original article treatment discontinuation and was censored at the date of the last followup visit for patients who did not discontinue early, who were still alive, and who had not progressed. Time to PD (TTPD) was the time from enrollment to the first observation of PD and was censored at the date of death for patients who had no documented PD at the time of death. TTPD was also censored at the time of initiation of other antitumor therapy for patients who did not have documented PD. Progression-free survival (PFS) was the time from enrollment to the first observation of PD or death from any cause and was censored at the date of the last follow-up visit for patients who were still alive and who had not progressed. OS was the time from enrollment to the time of death from any cause and was censored at the date of the last follow-up visit for patients who were still alive.
statistical methods
Tumor RR was calculated as the sum of the number of observed PRs and CRs divided by the number of patients enrolled. Time-to-objective tumor response was summarized using descriptive statistics. Duration of response, TTF, TTPD, PFS, and OS were estimated using Kaplan-Meier [22] .
Two-sided 95% confidence intervals (CIs) for tumor RR were calculated based on exact binomial probability. Drug toxicity was measured according to CTC v2.0 [20] . Dose intensity for gemcitabine and pemetrexed was measured as actual dose of drug administered divided by planned dose.
results patients
From December 2002 to August 2005, 63 patients were screened and 54 were enrolled in the trial. After 48 patients were enrolled, five patients were discovered to be inevaluable for efficacy (i.e. did not receive one or more doses of both study medications and/or did not have measurable disease) and were replaced with six additional patients. Enrolled patient characteristics are detailed in Table 1 . The majority of patients were male (59%), were Caucasian (91%), and had stage IV disease (91%) and adenocarcinoma pathology (63%). The average time from initial diagnosis to study enrollment was 2.6 months (median = 1.15 months). Approximately 25% of patients had received prior surgery, and 20% had received prior radiotherapy for early-stage disease. Table 2 summarizes the exposure to study medications. Of the 53 patients treated, 14 (26%) received six or more cycles and four (8%) completed eight or more cycles of therapy. Table 3 describes the reasons for dose adjustments. A total of 36 patients (68%) had one or more adjustment including dose delay (n = 12, 23%), dose omission (n = 14, 26%), and dose reduction (n = 26, 49%). Grade 3 or 4 neutropenia caused dose delays, omissions, or reductions in 26% of treated patients, and grade 3 or 4 thrombocytopenia was the reason for adjustment in 9% of treated patients. Dose adjustments occurred most frequently in cycles 2 (n = 21), 3 (n = 14), and 4 (n = 11). Of the 26 patients requiring dose reductions, 16 (62%) required two or more during study treatment. Among these, 12 patients required a second or third dose reduction due to continuing or additional hematologic toxic effects.
drug administration
antitumor activity
Of the 54 enrolled patients, none experienced a CR and seven (13%) experienced a PR, for a best overall RR of 13% (95% CI = 5% to 25%). Twenty-nine patients (54%; 95% CI = 40% to 67%) had SD (patients with unconfirmed CR or PR were included in this group). Nine patients (17%; 95% CI = 8% to 29%) experienced PD. The disease control rate (CR + PR + SD) was 67% (95% CI = 53% to 79%). Tumor response results were 
months).
Percent estimates of patients without treatment failure at 6 and 12 months were 17% and 2%, respectively. Median TTPD was 5.1 months (95% CI = 3.9-8.5; censored = 43%). Median PFS was 4.6 months (see Figure 1 ; 95% CI = 3.9, 7.2; censored = 6%). Median OS was 12.4 months (see Figure 2 ; 95% CI = 8.7-14.0; censored = 24%). Excluding the five patients who were inevaluable for efficacy, the best overall RR was 14% (95% CI = 6% to 27%); disease control rate was 73% (95% CI = 59% to 85%); median PFS was 4.6 months (95% CI = 3.9-7.2; censored = 6%); and median OS was 12.7 months (95% CI = 8.4-15.3; censored = 27%).
postprotocol treatment
Eighty-two percent of patients received one or more treatment modalities subsequent to study discontinuation, including radiotherapy (4%), surgery (30%), chemotherapy (76%), or other cancer therapy (13%). Patients received the following chemotherapeutic agents upon study discontinuation: carboplatin (37%), vinblastine (24%), docetaxel (24%), other unspecified agents (19%), paclitaxel (9%), cisplatin (4%), vinorelbine (4%), and gemcitabine (4%).
toxicity
The 53 patients who received at least one dose of gemcitabine and/or pemetrexed were included in the safety analysis. Table 4 summarizes the incidence of grade 3 or 4 hematologic and nonhematologic toxic effects. Neutropenia was the most common grade 3 or 4 hematologic toxicity, occurring in 40% of patients. Five patients (9%) experienced grade 3 febrile neutropenia and one (2%) experienced grade 4 febrile neutropenia. Grade 3 or 4 thrombocytopenia occurred in six patients (11%) and four (8%) required platelet transfusion. Grade 3 anemia was seen in three patients (6%) and 14 (26%) received packed red blood cell (PRBC) transfusions. Some patients received PRBC transfusions for grade 1 or 2 anemia events.
The most common grade 3 or 4 nonhematologic toxic effects were fatigue (21%), dyspnea (21%), and pneumonia (17%). Two of 11 grade 3 or 4 dyspnea and two of nine grade 3 or 4 pneumonia toxic effects were deemed treatment related. 
Other nonhematologic adverse events occurred in <2% of patients. N, number of patients. 
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Nausea, dehydration, and hypoxia were each reported in 9% of patients, and vomiting and deep-vein thrombosis were observed in 8%. Other grade 3 or 4 nonhematologic events occurred in <8% of patients. Five patients (9%) experienced grade 1 alopecia; no grade 2 alopecia was reported. Sixteen patients (30%) discontinued due to adverse events. One 78-year-old male experienced grade 4 neutropenia by day 12 of cycle 1, resulting in death due to pneumonia and sepsis on day 13. The investigator determined the death was treatment related.
discussion
This trial achieved an overall RR of 13%, lower than previously seen with other doublets and insufficient to warrant further phase III investigation according to the predefined efficacy threshold. PFS was similarly disappointing. In contrast, median OS in excess of 12 months is encouraging, although possibly attributable to indolent disease or effective postprotocol treatment versus the study regimen. Severe thrombocytopenia and febrile neutropenia occurred at unacceptable rates, given limited efficacy. Grade 3 or 4 dyspnea occurred in 17% of patients, but it is unclear whether this is truly related to study treatment or underlying disease (the latter suggested by the common appearance of dyspnea as an adverse effect with a wide range of treatment conditions for advanced NSCLC). The need for frequent dose adjustments implies that a lower gemcitabine dose maybe more appropriate for use in clinical practice or in future trials exploring this doublet. Several recent trials have demonstrated a survival advantage when patients with nonsquamous histology are treated with a pemetrexed-based regimen [23] [24] [25] [26] , and pemetrexed has recently received European Medicines Agency approval as firstline chemotherapy in nonsquamous subgroups, when combined with cisplatin. Table 5 summarizes the efficacy and safety results of the current study by tumor histology type. Overall, the comparison suggests modestly superior results from this regimen in patients with nonsquamous histology, although further elucidation would require a much larger clinical experience.
Previous studies of this combination have incorporated a 90-min delay between the gemcitabine and pemetrexed infusions [14] [15] [16] . A recent phase Ib study of gemcitabine plus pemetrexed reported no pharmacokinetic interactions between the drugs when the 90-min delay was eliminated, and no increased toxicity was observed [17] . In the current study, pemetrexed was administered immediately following day 8 gemcitabine, achieving gemcitabine and pemetrexed relative dose intensities of 84% and 83%, respectively. Disease control rate and survival were similar to earlier trials, suggesting no significant detriment associated with the removal of the 90-min delay. Table 6 compares the current study to previous phase I and II trials utilizing gemcitabine and pemetrexed.
In summary, this combination demonstrates minimal activity as first-line therapy for advanced NSCLC, although it maybe a feasible alternative to platinum-based regimens for selected patients. Administering day 8 gemcitabine and pemetrexed in rapid sequence appears not to negatively impact the therapeutic index, potentially improving the regimen's convenience for physician and patient. Nonetheless, a relatively low overall RR combined with a challenging hematologic toxicity profile limits its appeal. (9) 1 (2) 6 (11) 9 (4) Thrombocytopenia 4 (8) 2 (4) Pleural effusion
One enrolled patient never received study treatment and was excluded from the safety analysis. N, number of patients; n, number in subgroup. Based on safety population (n = 53): squamous histology (n = 9); nonsquamous histology (n = 44). n, number in subgroup; CI, confidence interval; PFS, progression-free survival; OS = overall survival. 
